Kentucky Kytril and Zofran Average Wholesale Price Lawsuit
GlaxoSmithKline agreed to pay the Commonwealth of Kentucky $3.75 million to settle allegations of deceptive or false marketing of the anti-nausea drugs Kytril and Zofran. Kentucky alleged that GSK improperly inflated the average wholesale price (AWP) for the drugs, causing Kentucky’s Medicaid program to pay millions of dollars more in reimbursements than it should have. Despite the fact that GSK was found liable in an earlier trial, GSK was allowed to settle without admitting any liability or wrongdoing.
- Misconduct Type
- Defective Pricing
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement